The reliable operation of power grid secondary equipment is an important guarantee for the safety and stability of the power system.However,various defects could be produced in the secondary equipment during longtermo...The reliable operation of power grid secondary equipment is an important guarantee for the safety and stability of the power system.However,various defects could be produced in the secondary equipment during longtermoperation.The complex relationship between the defect phenomenon andmulti-layer causes and the probabilistic influence of secondary equipment cannot be described through knowledge extraction and fusion technology by existing methods,which limits the real-time and accuracy of defect identification.Therefore,a defect recognition method based on the Bayesian network and knowledge graph fusion is proposed.The defect data of secondary equipment is transformed into the structured knowledge graph through knowledge extraction and fusion technology.The knowledge graph of power grid secondary equipment is mapped to the Bayesian network framework,combined with historical defect data,and introduced Noisy-OR nodes.The prior and conditional probabilities of the Bayesian network are then reasonably assigned to build a model that reflects the probability dependence between defect phenomena and potential causes in power grid secondary equipment.Defect identification of power grid secondary equipment is achieved by defect subgraph search based on the knowledge graph,and defect inference based on the Bayesian network.Practical application cases prove this method’s effectiveness in identifying secondary equipment defect causes,improving identification accuracy and efficiency.展开更多
Oral drug delivery,which requires surviving the harsh environment in the gastrointestinal(Gl)tract and penetrating the intestinal epithelium,has not bee n achieved using simple formulatio n nan oparticles(NPs).Medici ...Oral drug delivery,which requires surviving the harsh environment in the gastrointestinal(Gl)tract and penetrating the intestinal epithelium,has not bee n achieved using simple formulatio n nan oparticles(NPs).Medici nal natural products(MNPs)have bee n widely used in traditi onal medicine for disease management through oral consumption.However,most pharmacologically active compounds within MNPs do not have the properties suitable for oral applicatio ns.We hypothesize that some MNPs contain n atural nano materials that can convert those compounds into oral formulations by forming NPs.After screening 66 MNPs,we identified five classes of small molecules that form NPs,many of which are capable of efficient drug encapsulation and Gl penetration.We show that one of them,dehydrotrametenolic acid(DTA),is capable of mediating oral delivery for effective disease treatment.We determined that DTA NPs assemble through hydrogen bonding and penetra怕the Gl tract via apical sodium-depe ndent bile acid tran sporter.Our study reveals a no vel class of single comp orient,small molecule-assembled NPs for oral drug delivery,and suggests a n ovel approach to modernizi ng MNPs through nano material discovery.展开更多
Stroke is the leading cause of death and disability.Currently,there is no effective pharmacological treatment for this disease,which can be partially attributed to the inability to efficiently deliver therapeutics to ...Stroke is the leading cause of death and disability.Currently,there is no effective pharmacological treatment for this disease,which can be partially attributed to the inability to efficiently deliver therapeutics to the brain.Here we report the development of natural compound-derived nanoparticles(NPs),which function both as a potent therapeutic agent for stroke treatment and as an efficient carrier for drug delivery to the ischemic brain.First,we screened a collection of natural nanomaterials and identified betulinic acid(BA)as one of the most potent antioxidants for stroke treatment.Next,we engineered BA NPs for preferential drug release in acidic ischemic tissue through chemically converting BA to betulinic amine(BAM)and for targeted drug delivery through surface conjugation of AMD3100,a CXCR4 antagonist.The resulting AMD3100-conjugated BAM NPs,or A-BAM NPs,were then assessed as a therapeutic agent for stroke treatment and as a carrier for delivery of NA1,a neuroprotective peptide.We show that intravenous administration of A-BAM NPs effectively improved recovery from stroke and its efficacy was further enhanced when NA1 was encapsulated.Due to their multifunctionality and significant efficacy,we anticipate that A-BAM NPs have the potential to be translated both as a therapeutic agent and as a drug carrier to improve the treatment of stroke.展开更多
基金supported by the State Grid Southwest Branch Project“Research on Defect Diagnosis and Early Warning Technology of Relay Protection and Safety Automation Devices Based on Multi-Source Heterogeneous Defect Data”.
文摘The reliable operation of power grid secondary equipment is an important guarantee for the safety and stability of the power system.However,various defects could be produced in the secondary equipment during longtermoperation.The complex relationship between the defect phenomenon andmulti-layer causes and the probabilistic influence of secondary equipment cannot be described through knowledge extraction and fusion technology by existing methods,which limits the real-time and accuracy of defect identification.Therefore,a defect recognition method based on the Bayesian network and knowledge graph fusion is proposed.The defect data of secondary equipment is transformed into the structured knowledge graph through knowledge extraction and fusion technology.The knowledge graph of power grid secondary equipment is mapped to the Bayesian network framework,combined with historical defect data,and introduced Noisy-OR nodes.The prior and conditional probabilities of the Bayesian network are then reasonably assigned to build a model that reflects the probability dependence between defect phenomena and potential causes in power grid secondary equipment.Defect identification of power grid secondary equipment is achieved by defect subgraph search based on the knowledge graph,and defect inference based on the Bayesian network.Practical application cases prove this method’s effectiveness in identifying secondary equipment defect causes,improving identification accuracy and efficiency.
基金This work was supported by NIH(Nos.NS095817(J.Z.)and 18TPA34170180(J.Z.))the National Natural Science Foundation of China(NSFC)(Nos.31770614(C.M.),21233003(L.F.),and 21573019(L.F.)).
文摘Oral drug delivery,which requires surviving the harsh environment in the gastrointestinal(Gl)tract and penetrating the intestinal epithelium,has not bee n achieved using simple formulatio n nan oparticles(NPs).Medici nal natural products(MNPs)have bee n widely used in traditi onal medicine for disease management through oral consumption.However,most pharmacologically active compounds within MNPs do not have the properties suitable for oral applicatio ns.We hypothesize that some MNPs contain n atural nano materials that can convert those compounds into oral formulations by forming NPs.After screening 66 MNPs,we identified five classes of small molecules that form NPs,many of which are capable of efficient drug encapsulation and Gl penetration.We show that one of them,dehydrotrametenolic acid(DTA),is capable of mediating oral delivery for effective disease treatment.We determined that DTA NPs assemble through hydrogen bonding and penetra怕the Gl tract via apical sodium-depe ndent bile acid tran sporter.Our study reveals a no vel class of single comp orient,small molecule-assembled NPs for oral drug delivery,and suggests a n ovel approach to modernizi ng MNPs through nano material discovery.
基金supported by Grant NS110721(JZ,KNS),EB023366(FH),EB011968(FH),CA140102(FH)from the NIH,United States,and Grants 18TPA34170180 and 19CSLOI34770004(JZ)from the AHA,United States.
文摘Stroke is the leading cause of death and disability.Currently,there is no effective pharmacological treatment for this disease,which can be partially attributed to the inability to efficiently deliver therapeutics to the brain.Here we report the development of natural compound-derived nanoparticles(NPs),which function both as a potent therapeutic agent for stroke treatment and as an efficient carrier for drug delivery to the ischemic brain.First,we screened a collection of natural nanomaterials and identified betulinic acid(BA)as one of the most potent antioxidants for stroke treatment.Next,we engineered BA NPs for preferential drug release in acidic ischemic tissue through chemically converting BA to betulinic amine(BAM)and for targeted drug delivery through surface conjugation of AMD3100,a CXCR4 antagonist.The resulting AMD3100-conjugated BAM NPs,or A-BAM NPs,were then assessed as a therapeutic agent for stroke treatment and as a carrier for delivery of NA1,a neuroprotective peptide.We show that intravenous administration of A-BAM NPs effectively improved recovery from stroke and its efficacy was further enhanced when NA1 was encapsulated.Due to their multifunctionality and significant efficacy,we anticipate that A-BAM NPs have the potential to be translated both as a therapeutic agent and as a drug carrier to improve the treatment of stroke.
